Angiotensin III is not just a breakdown product of angiotensin II — it's a physiologically active peptide that produces comparable effects on blood pressure, fluid balance, and cardiovascular disease.
Comparable to Ang IIAngiotensin III produces physiologically relevant effects similar to angiotensin II on blood pressure, blood volume, sodium handling, and disease pathology
What the researchers found
Angiotensin III (Ang III), long considered a minor degradation product of angiotensin II, actually produces physiologically relevant effects comparable to Ang II. The review establishes that Ang III is a biologically active peptide in its own right within the renin-angiotensin system (RAS), with its own spectrum of effects on blood pressure, blood volume, sodium handling, thirst, and vasopressin release.
The RAS contains multiple active peptides — angiotensinogen, Ang II, Ang III, Ang IV, and Ang-(1-7) — each with distinct physiological roles. While research has overwhelmingly focused on Ang II, emerging data shows Ang III may be equally important in driving the pathological effects seen in heart failure, hypertension, heart attack, and diabetic kidney disease.
Why it matters
The renin-angiotensin system is one of the most important drug targets in medicine — ACE inhibitors and ARBs are among the most widely prescribed medications. Yet most research has focused almost exclusively on angiotensin II. Recognizing Ang III as a physiologically relevant peptide opens new therapeutic possibilities and may explain why some patients don't respond fully to current RAAS-targeting drugs.
The numbers in context
Review covers: AGT, Ang II, Ang III, Ang IV, Ang-(1-7) · Diseases: heart failure, hypertension, MI, diabetic nephropathy · Multiple receptor types and signal transduction mechanisms
How the study worked
This is a narrative review synthesizing published research on angiotensin III's physiological effects across multiple organ systems. The authors compiled evidence from animal studies, cell-based experiments, and clinical observations to build a comprehensive picture of Ang III's role within the RAS.
Who was studied
Review of research across animal and human studies
What this study cannot tell us
As a narrative review, it does not follow systematic review methodology and may not capture all available evidence. Much of the Ang III data comes from animal studies, and the relative contribution of Ang III versus Ang II in human disease is still being defined. The review does not provide quantitative comparisons of potency between the angiotensin peptides.
How to read the evidence
This is a narrative review that synthesizes a broad body of research on Ang III. It provides a comprehensive overview but does not present new data or follow systematic review methodology.
When this study was published
Published in 2013, this review remains relevant as a foundational reference for understanding angiotensin III. The broader RAS peptide field continues to expand, with recent work on Ang-(1-7) and other fragments further supporting the multi-peptide complexity described here.
The bigger picture
The renin-angiotensin system is far more complex than the simple angiotensinogen → Ang I → Ang II pathway taught in textbooks. Ang III, Ang IV, and Ang-(1-7) each have distinct biological roles. As this complexity becomes better understood, it could lead to more precisely targeted therapies — for example, drugs that block Ang III specifically while preserving beneficial effects of other angiotensin peptides.
Questions still open
- Should blood pressure medications be designed to target angiotensin III as well as angiotensin II?
- Does angiotensin III play a larger role in certain diseases (like diabetic nephropathy) compared to angiotensin II?
- Could angiotensin III levels serve as an additional biomarker for cardiovascular risk assessment?
Common questions
What's the difference between angiotensin II and angiotensin III?
Do current blood pressure medications block angiotensin III?
Read the original research
Angiotensin III: a physiological relevant peptide of the renin angiotensin system.
Peptides, 46, 26-32
Citation
Yugandhar, Vudhya G; Clark, Michelle A. (2013). Angiotensin III: a physiological relevant peptide of the renin angiotensin system.. Peptides, 46, 26-32. https://doi.org/10.1016/j.peptides.2013.04.014